Literature DB >> 18664927

FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.

José Figueras-Aloy1, Xavier Carbonell-Estrany, José Quero-Jiménez, Belén Fernández-Colomer, Juana Guzmán-Cabañas, Iñaqui Echaniz-Urcelay, Eduardo Doménech-Martínez.   

Abstract

BACKGROUND: Ex-premature infants are more predisposed to complicated primary respiratory syncytial virus (RSV) infection. The aim of the present study was to validate the risk factors found in a previous epidemiologic case-control study regarding hospitalization as a result of RSV infection in premature infants born at 32-35 weeks of gestational age (WGA) in Spain.
METHODS: A prospective 2-cohort study was conducted during the 2005-2006 (October 2005 to April 2006) and 2006-2007 (October 2006 to April 2007) RSV seasons, respectively. Cases were premature infants hospitalized for RSV infection whereas controls were premature infants of the same age who did not require any hospitalization for respiratory causes.
RESULTS: During the study period 5441 children from 37 Spanish hospitals were included in the risk factor analysis. Two hundred two (3.7%) were cases and the rest controls. Of the cases, 17.8% were admitted to the intensive care unit and 7.4% required mechanical ventilation. None of the patients died. Logistic regression analysis demonstrated that the risk of RSV-related respiratory infection requiring hospital admission in preterm infants (32-35 WGA) was associated with the following factors: absolute chronologic age of < or = 10 weeks at the onset of RSV season [odds ratio (OR): 2.99; 95% confidence interval (CI): 2.23-4.01]; presence of school-age siblings or day care attendance (OR: 2.04; 95% CI: 1.53-2.74); and smoking during pregnancy (OR: 1.61; 95% CI: 1.16-2.25).
CONCLUSIONS: In premature infants (32-35 WGA), only 3 independent risk factors were found to significantly increase the risk of RSV-related respiratory infection and hospitalization.

Entities:  

Mesh:

Year:  2008        PMID: 18664927     DOI: 10.1097/INF.0b013e3181710990

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  40 in total

1.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 3.  Management of acute viral bronchiolitis in children: Evidence beyond guidelines.

Authors:  Shaikh Mohammed Iqbal
Journal:  Sudan J Paediatr       Date:  2012

4.  Preventing hospitalizations for respiratory syncytial virus infection.

Authors:  Joan L Robinson; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2015 Aug-Sep       Impact factor: 2.253

5.  RSV infection among children born moderately preterm in a community-based cohort.

Authors:  Rolof G P Gijtenbeek; Jorien M Kerstjens; Sijmen A Reijneveld; Eric J Duiverman; Arend F Bos; Elianne J L E Vrijlandt
Journal:  Eur J Pediatr       Date:  2014-09-06       Impact factor: 3.183

6.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

Review 7.  Glucocorticoids for acute viral bronchiolitis in infants and young children.

Authors:  Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 8.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 9.  Prematurity and the burden of influenza and respiratory syncytial virus disease.

Authors:  Bernhard Resch; Stefan Kurath-Koller; Monika Eibisberger; Werner Zenz
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

Review 10.  Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.

Authors:  Joseph R DiFranza; Anthony Masaquel; Amy M Barrett; Ann D Colosia; Parthiv J Mahadevia
Journal:  BMC Pediatr       Date:  2012-06-21       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.